title: Natriuretic peptides and primary prevention: the new world?
authors.affiliation: Duke Clinical Research Institute, Durham, North Carolina. Electronic address: michael.felker@duke.edu.
authors.forename: G Michael
authors.initials: GM
authors.lastname: Felker
authors.forename: Tariq
authors.initials: T
authors.lastname: Ahmad
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology*; D005260:Female; D006331:Heart Diseases / Q000517:prevention & control*; D006801:Humans; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain
keywords: NT-proBNP-selected; RAS antagonists; beta-blocker; diabetes mellitus; primary prevention